Loading stock data…
CDXS
$2.47-0.13 (-5.18%)
After Hours$2.46-0.01 (-0.40%)· Last close Jun 9
Codexis, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Codexis, Inc. in the Healthcare sector is trading at $2.47. Wall Street consensus targets $6.58 (6 analysts), implying a +166.5% move over the next 12 months. The stock is currently 36% below its 52-week high of $3.87, remaining 21.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +166.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$2.47
Potential Downside
0%
Whystock Fair Value$2.47
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-73.99%
Volume
Today's trading volume
1.05M
Recent News
Spotlight On Promising Penny Stocks For May 2026
Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, investors may find value in smaller or newer companies that offer growth potential at lower price points. Penny stocks, though an outdated term, still represent a viable investment area for those seeking opportunities in companies with strong financial health and long-term potential.
Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58
A week ago, Codexis, Inc. ( NASDAQ:CDXS ) came out with a strong set of first-quarter numbers that could potentially...
Codexis (CDXS) Q1 2026 Earnings Transcript
Need a quote from a Motley Fool analyst? Alison Moore: Thank you, Georgia, and thanks, everyone, for joining. While it's been a short 8 weeks since our last call, we've accomplished a lot at Codexis.
Codexis, Inc. Q1 2026 Earnings Call Summary
Moby summary of Codexis, Inc.'s Q1 2026 earnings call
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +9.09% and +1.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?